DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

Alnylam Pharmaceuticals

Status: Enrolling

Conditions: Transthyretin Amyloidosis With Cardiomyopathy

Study type: Observational

Funder types: Industry

Identifiers

NCT07358078

ALN-TTRSC02-008

Details and patient eligibility

About

The purpose of this study is to:

• Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care
• Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care
• Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care
• Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care

Full description

Each site will invite all eligible patients to participate. Patients will be followed for up to 5 years or until patient withdrawal of consent, loss to follow-up, death, or the end of the study, whichever comes first.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Has a diagnosis of ATTR-CM
• Is initiating treatment with vutrisiran or another approved ATTR-CM therapy

Exclusion criteria

• Is enrolled in an interventional clinical trial

Trial design

2,000 participants in 1 patient group

Patients with ATTR-CM

Description:

Patients with ATTR-CM.